Previous 10 | Next 10 |
PAVmed and Lucid Chairman and Chief Executive Officer, Dr. Lishan Aklog, Testifies at U.S. House of Representatives Energy and Commerce Committee, Hearing on Life-Saving Innovations and Medicare Coverage PR Newswire Advocated stronger transparency and predictability, and inclu...
PAVmed Receives 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement PR Newswire NEW YORK , June 28, 2023 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical tec...
PAVmed to Participate in Healthcare Virtual Conference Presented by Maxim Group LLC PR Newswire Dr. Lishan Aklog , PAVmed CEO, to participate in Fireside Chat with Maxim's Anthony Vendetti on Wednesday, June 21, 2023 , at 1:30 PM ET . NEW YORK , ...
Lucid Diagnostics Launches First EsoGuard® Mobile Test Unit PR Newswire First esophageal precancer detection event utilizing an EsoGuard mobile test unit to be hosted today by Florida Digestive Health Specialists in Sarasota, Florida NEW YORK , June 5, 2...
PAVmed Digital Health Subsidiary, Veris Health, Joins Cancer Moonshot's CancerX Partnership as Founding Member PR Newswire NEW YORK , June 2, 2023 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) ("PAVmed"), a diversified commercial-stage medical te...
2023-05-16 19:39:08 ET Lucid Diagnostics Inc. (LUCD) Q1 2023 Results Conference Call May 16, 2023 08:30 AM ET Company Participants Michael Parks - VP, IR Dr. Lishan Aklog - Chairman and CEO Dennis McGrath - CFO Conference Call Participants Alex Vukasi...
PAVmed Provides Business Update and First Quarter Financial Results PR Newswire EsoGuard ® test volume gains momentum as Lucid expands high-volume testing events PAVmed appoints President for Veris Health and expands commercial footprint Conference cal...
2023-05-16 02:41:11 ET Lucid Diagnostics press release ( NASDAQ: LUCD ): Q1 Non-GAAP EPS of -$0.24 beats by $0.06 . Revenue of $0.4M (+100.0% Y/Y) beats by $0.17M . Lucid had cash and cash equivalents of $39.5 million as of March 31, 2023, compared to $22.5 mil...
Lucid Diagnostics Provides Business Update and First Quarter Financial Results PR Newswire EsoGuard ® test volume increases 57 percent sequentially and 245 percent year-on-year Conference call and webcast to be held tomorrow, May 16 th at 8:30 AM EST...
2023-05-12 15:00:44 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...
News, Short Squeeze, Breakout and More Instantly...
Lucid Diagnostics Inc. Company Name:
LUCD Stock Symbol:
NASDAQ Market:
Lucid Diagnostics Inc. Website:
Lucid Diagnostics Launches New Corporate Website PR Newswire NEW YORK , July 11, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-ow...
Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population PR Newswire Prospective screening study demonstrates excellent EsoGuard s...
4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard® Esophageal Precancer Testing PR Newswire Firefighter #CheckYourFoodTube Precancer Testing Event organized by Mass General Brigham physicians and Boston Firefighters Local 718 IAFF NEW YORK , June...